Literature DB >> 12459731

Molecular mechanisms of novel therapeutic approaches for multiple myeloma.

Teru Hideshima1, Kenneth C Anderson.   

Abstract

Multiple myeloma remains largely incurable despite conventional and high-dose therapies, and so novel biologically based treatment approaches are urgently required. Recent studies have characterized the molecular mechanisms by which multiple myeloma cell-host bone-marrow interactions regulate tumour cell growth, survival and migration in the bone-marrow microenvironment. These studies have not only enhanced our understanding of disease pathogenesis, but have also provided the framework for a new treatment model that targets the multiple myeloma cell in its bone-marrow microenvironment to overcome drug resistance and improve patient outcome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12459731     DOI: 10.1038/nrc952

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  102 in total

1.  Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

Authors:  Loredana Santo; Teru Hideshima; Andrew L Kung; Jen-Chieh Tseng; David Tamang; Min Yang; Matthew Jarpe; John H van Duzer; Ralph Mazitschek; Walter C Ogier; Diana Cirstea; Scott Rodig; Homare Eda; Tyler Scullen; Miriam Canavese; James Bradner; Kenneth C Anderson; Simon S Jones; Noopur Raje
Journal:  Blood       Date:  2012-01-19       Impact factor: 22.113

Review 2.  Oncogenic activation of NF-kappaB.

Authors:  Louis M Staudt
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

Review 3.  Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity.

Authors:  Wan Zhang; Peng Huang
Journal:  Cancer Biol Ther       Date:  2011-01-15       Impact factor: 4.742

4.  Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.

Authors:  Bernard Regidor; Marissa-Skye Goldwater; Jessica Wang; Sean Bujarski; Regina Swift; Benjamin Eades; Marsiye Emamy-Sadr; Shahrooz Eshagian; Gary Schwartz; Tanya M Spektor; James R Berenson
Journal:  Ann Hematol       Date:  2021-05-14       Impact factor: 3.673

Review 5.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

6.  Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.

Authors:  Shuji Ozaki; Osamu Tanaka; Shiro Fujii; Yuri Shigekiyo; Hirokazu Miki; Masahito Choraku; Kumiko Kagawa; Jin Asano; Kyoko Takeuchi; Ken-ichi Kitazoe; Toshihiro Hashimoto; Masahiro Abe; Toshio Matsumoto
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

Review 7.  Global gene expression profiling in the study of multiple myeloma.

Authors:  John D Shaughnessy
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

8.  Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.

Authors:  Naoya Mimura; Teru Hideshima; Toshiyasu Shimomura; Rikio Suzuki; Hiroto Ohguchi; Ola Rizq; Shohei Kikuchi; Yasuhiro Yoshida; Francesca Cottini; Jana Jakubikova; Diana Cirstea; Gullu Gorgun; Jiro Minami; Yu-Tzu Tai; Paul G Richardson; Teruhiro Utsugi; Atsushi Iwama; Kenneth C Anderson
Journal:  Cancer Res       Date:  2014-06-16       Impact factor: 12.701

9.  Berbamine, a novel nuclear factor kappaB inhibitor, inhibits growth and induces apoptosis in human myeloma cells.

Authors:  Yun Liang; Rong-Zhen Xu; Lei Zhang; Xiao-Ying Zhao
Journal:  Acta Pharmacol Sin       Date:  2009-12       Impact factor: 6.150

10.  The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.

Authors:  James J Driscoll; Dheeraj Pelluru; Konstantinos Lefkimmiatis; Mariateresa Fulciniti; Rao H Prabhala; Philip R Greipp; Bart Barlogie; Yu-Tzu Tai; Kenneth C Anderson; John D Shaughnessy; Christina M Annunziata; Nikhil C Munshi
Journal:  Blood       Date:  2009-11-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.